Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhCC10 for premature neonates with respiratory distress syndrome
2015-000253-21Phase 2
- Sponsor
- Therabron Therapeutics
- Start
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of recombinant human club cell 10 kDa protein in respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Therabron Therapeutics. Primary endpoint: Survival without chronic respiratory morbidity at 12 months corrected gestational age.
02
Drugs
recombinant human club cell 10 kDa protein
03
Conditions
respiratory distress syndrome (RDS)bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2015-000253-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000253-21.